Omnicell OMCL underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light ...

Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q4 CY2024 results , with sales up 18.6% year on year to $306.9 million. On the other hand, next quarter’s revenue guidance of $260 million ...

Omnicell, Inc. OMCL has witnessed strong momentum in the past year. Shares of the company have risen 41.6% against a 11.3% decline of the industry during the same time frame. The S&P 500 composite ...